Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration

Abstract

The purpose of this study was to evaluate the systemic effects of intravitreal ranibizumab (Lucentis) treatment in patients with neovascular age-related macular degeneration (AMD). The impact of intravitreal ranibizumab injections on central retinal thickness (CRT) of treated and contralateral untreated eyes, and differences in gene expression patterns in the peripheral blood mononuclear cells were analyzed. The study included 29 patients aged 50 years old and over with diagnosed neovascular AMD. The treatment was defined as 0.5 mg of ranibizumab injected intravitreally in the form of one injection every month during the period of 3 months. CRT was measured by optical coherence tomography. The gene expression profile was assigned using oligonucleotide microarrays of Affymetrix HG-U133A. Studies have shown that there was a change of CRT between treated and untreated eyes, and there were differences in CRT at baseline and after 1, 2, and 3 months of ranibizumab treatment. Three months after intravitreal injection, mean CRT was reduced in the treated eyes from 331.97±123.62 to 254.31±58.75 μm, while mean CRT in the untreated fellow eyes reduced from 251.07±40.29 to 235.45±36.21 μm at the same time. Furthermore, the research has shown that among all transcripts, 3,097 expresses change after the ranibizumab treatment in relation to controls. Among these transcripts, 1,339 were up-regulated, whereas 1,758 were down-regulated. Our results show the potential systemic effects of anti-VEGF therapy for AMD. Moreover, our study indicated different gene expression in peripheral blood mononuclear cells before and after intravitreal ranibizumab treatment.

Keywords:

• ranibizumab
• contralateral eye
• central retinal thickness
• oligonucleotide microarray

View correction statement:

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]

Introduction

Age-related macular degeneration (AMD) is the most common cause of severe, irreversible vision loss in the elderly.¹ In the last decades, therapies for neovascular AMD treatments were: photodynamic therapy, thermal laser photocoagulation, or transpupillary thermotherapy. Currently, the most widely used treatments for the neovascular exudative form of AMD include intravitreal injections of anti-VEGF agents, such as ranibizumab (Lucentis), aflibercept, or bevacizumab.²

Anti-VEGF therapies have been used with increasing frequency to treat other ocular diseases, including diabetic macular edema,³ branch retinal vein occlusion, central retinal vein occlusion,⁴ and uveitis.^5,6

The use of anti-VEGF drugs improved visual prognosis of AMD patients.¹ It is also suggested that anti-VEGF agents may reach the contralateral eye via the systemic circulation.^7,8 However, the effects of intravitreal injections of anti-VEGFs on untreated contralateral eyes are not well documented. Moreover, systemic side effects of intraocular anti-VEGF therapy for AMD are also not well-known.⁹ Previous studies suggested that this therapy may lead to serious cardiovascular complications.^1,10,11 On the contrary, Campbell et al observed that anti-VEGF therapy is not associated with increased risk of stroke.¹² Moreover, there are only few published data regarding gene expression/protein level differences in blood samples of patients with AMD after intravitreal anti-VEGF treatment.^13–15 Nassar et al suggested that selected cytokine serum levels may be used as biomarkers for AMD or to predict patient responses to anti-VEGF therapies.¹³

The purpose of this study was to evaluate the systemic effects of intravitreal ranibizumab treatment in patients with neovascular AMD. The influence of intravitreal ranibizumab injections on central retinal thickness (CRT) of treated and contralateral untreated eyes, as well as the differences in gene expression patterns in the peripheral blood mononuclear cells (PBMCs) of these patients were analyzed.

Materials and methods

Subjects

The study included 29 patients (15 women and 14 men, mean age 73 years, range: 54–86 years) who received ranibizumab because of neovascular AMD diagnosed based on routine ophthalmologic diagnostic procedures (optical coherence tomography [OCT] and fluorescein angiography). All the patients were treated at the Department of Ophthalmology, University Hospital No 5, Medical University of Silesia, Katowice, Poland.

All subjects underwent a complete ophthalmic examination: best-corrected visual acuity using Snellen charts, Goldmann applanation tonometry, indirect biomicroscopy in mydriasis (+78 D lens; Volk Optical, Mentor, OH, USA), OCT (Cirrus HD-OCT 4000, Carl Zeiss Meditec AG, Jena, Germany) and fluorescein angiography (Fundus Camera FF 450 plus IR; Carl Zeiss Meditec AG).

The inclusion criteria for the study group were as follows: choroidal neovascularization (CNV) resulting from AMD, aged ≥50 years, best-corrected visual acuity 0.1 to 0.5 with Snellen chart and no previous CNV therapies, such as anti-VEGF injections, photodynamic, or laser therapies. Patients with uncontrolled, elevated intraocular pressure, glaucomatous optic neuropathy, chronic uveitis, retinal vein occlusion, or other ocular neovascular diseases were excluded from the study. Moreover, patients with a previous history of myocardial infarction or stroke were also excluded. Intravitreal injections were performed by an ophthalmologist, who applied an aseptic technique of the procedure, using infiltration anesthesia in the injection site. The treatment was defined as 0.5 mg (0.05 mL) of ranibizumab (Lucentis, Novartis International AG, Basel, Switzerland) injected intravitreally in the form of one injection every month during the period of 3 months. The reinjections were dependent on CNV activity. The study was approved by the Bioethics Committee of the Medical University in Katowice (KNW) in accordance with the Declaration of Helsinki regarding medical research involving human subjects. All patients were informed about the research and signed an informed consent form.

Tissues

For molecular analysis venous blood samples were collected into ethylenediaminetetraacetic acid-containing tubes before ranibizumab injections and 30 days after the application of three injections of Lucentis at around the same time of day. PMBCs were isolated from 5 mL specimens derived from each patient by using Ficoll-Conray density gradient centrifugation for 30 minutes at 1,500 rpm at room temperature immediately after blood collection (specific gravity 1.077; Immunobiological Co., Gunma, Japan).

RNA extraction

Total RNA was extracted using the TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. RNA extracts were treated with DNase I (RNeasy Mini Kit; Qiagen NV, Venlo, the Netherlands) according to the manufacturer’s instructions. The quality of extracts was checked electrophoretically using 0.9% agarose gel stained with ethidium bromide (Sigma-Aldrich Co., St Louis, MO, USA). The results were analyzed and recorded using the 1D Bas-Sys gel documentation system (Biotech-Fisher, Perth, Australia). Nucleic acid concentration was determined using a GeneQuant II RNA/DNA spectrophotometer (Pharmacia Biotech, Cambridge, UK).

Oligonucleotide microarray analysis

Eight samples of patients with AMD were collected for microarray analysis (control – three samples; after ranibizumab treatment – five samples) before and after intravitreal ranibizumab injections. The injections were conducted every month during a 3-month period. The analysis of the expression profile of genes was performed using commercially available oligonucleotide microarrays of HG-U133A (Affymetrix, Santa Clara, CA, USA) in accordance with the manufacturer’s recommendations, as described previously.¹⁶ Each gene chip contains 22,238 probe sets that correspond to more than 18,400 transcripts and 14,500 well-characterized human genes. Here, approximately 8 μg of total RNA were used for the complementary DNA (cDNA) synthesis using SuperScript Choice System (Thermo Fisher Scientific). During the next step, cDNA was used as a template to produce biotin-labeled complementary RNA (cRNA) using BioArray HighYield RNA transcript labeling kit (Enzo Life Sciences, Farmingdale, NY, USA). cRNA was purified on Rneasy Mini Kit columns (Qiagen NV). Next, the biotin-labeled cRNA was fragmented using Sample Cleanup Module (Qiagen NV) and hybridized with the HG-U133A microarray (Affymetrix). The cRNA probes hybridized to oligonucleotide arrays were stained with streptavidin phycoerythrin conjugate and were scanned using GeneArray Scanner G2500A (Agilent Technologies, Santa Clara, CA, USA). The scanned data were processed for signal values using Microarray Suite 5.0 software (Affymetrix). The obtained results were normalized using RMAExpress software (Robust Multichip Average).

Statistical analyses

Statistical analyses were performed using Statistica 9.0 software (StatSoft, Tulsa, OK, USA), and the level of significance was set at P<0.05. Values were expressed as mean and standard deviation. The differences of repeated measures of continuous variables were analyzed with the two-factor analysis of variance (ANOVA) for repeated measures. Paired t-test was used to assess the significant differences between CRT at baseline and after ranibizumab treatment in treated and untreated contralateral eyes.

The data from all arrays were analyzed using Gene-Spring 12.0 platform (Agilent Technologies) to identify transcriptome differences between the control and ranibizumab treatment groups. The oligonucleotide microarrays of Affymetrix HG-U133A enabled an analysis of 22,283 mRNA transcripts. The normalized data were used to compile a list of genes, the expression of which appeared to be up- or down-regulated by an arbitrary, at least 2-fold, cutoff. A significant differential gene expression was identified by 2.0-fold change at P<0.05 (t-test). The Benjamin–Hochberg false discovery rate multiple test correction was applied whenever applicable. Gene ontology analysis was carried out with the PANTHER 8.0 (Protein Analysis Through Evolutionary Relationships; http://www.pantherdb.org) Classification System database to classify genes based on their biological processes, molecular functions, cellular components, and pathways.

Results

The differences in CRT between ranibizumab treated and untreated contralateral eyes

In all patients, CRT was measured by OCT in both eyes: before the first dose of treatment was administered (baseline) and again at 1, 2, and 3 months after the initiation of treatment in treated eye and untreated contralateral eyes. There was a statistically significant change of CRT between treated and untreated eyes (ANOVA for repeated measures, P=0.0028). Moreover, there were statistically significant differences in CRT at baseline and after 1, 2, and 3 months of ranibizumab treatment (ANOVA for repeated measures, P<0.0001) (Figure 1). The mean CRT decreased over time in both groups, with a sharper decrease in the treatment group. The differences in CRT between treated and untreated contralateral eyes means have been narrowing over time (ANOVA for repeated measures, P=0.0004) (Figure 1).

Figure 1 The differences in central retinal thickness (CRT) over time in treated and untreated contralateral eyes.

Note: Data presented as mean with 95% CI, P<0.05, ANOVA for repeated measures.
Abbreviations: CI, confidence interval; ANOVA, analysis of variance.

While mean CRT was significantly reduced in the treated eyes 3 months after intravitreal injection from 331.97±123.62 to 254.31±58.75 μm (paired t-test, P<0.0001) (Figure 2A), mean CRT in the untreated fellow eyes reduced significantly from 251.07±40.29 to 235.45±36.21 μm 3 months later (paired t-test, P=0.0405) (Figure 2B).

Figure 2 The central retinal thickness (CRT) measured by optical coherence tomography before the first dose of treatment and 3 months after the initiation of treatment in treated and untreated contralateral eyes.

Notes: (A) Treated and (B) untreated contralateral eyes. Box and whisker plots present mean ± SE and SD of central retinal thickness; *P<0.05, paired t-test.
Abbreviations: SE, standard error; SD, standard deviation.

The differences in gene expression profile before and after ranibizumab treatment

During the next step of the research, the gene expression profile was assigned using oligonucleotide microarrays of Affymetrix HG-U133A, enabling analysis of 22,283 mRNA transcripts. The expression of genes was compared in PBMCs of AMD patients before and after ranibizumab treatment. Among all transcripts, 3,097 for 2,806 genes expressed more than 2-fold statistically significant change after ranibizumab treatment in relation to controls (Table 1). Among these transcripts, 1,339 for 1,137 genes were up-regulated, whereas 1,758 for 1,669 genes were down-regulated. Gene ontology analysis identified 14 subgroups for differentially expressed genes at P<0.05 based on biological processes (Figure 3A), ten subgroups based on molecular functions (Figure 3B), and seven subgroups based on cellular components (Figure 3C). In the last part of the study, PANTHER analysis revealed several functional categories that were significantly enriched in statistically differentially expressed gene set compared to the entire National Center for Biotechnology Information reference list of human genome based on biological processes, molecular functions, and cellular components of these genes (Table 2). Moreover, PANTHER pathway analysis revealed that differentially up-regulated genes were enriched for several molecular pathways, including CCKR signaling map (21 genes), T-cell activation (13 genes), ubiquitin proteasome pathways (eleven genes), p53 pathways (12 genes), glycolysis (six genes), integrin signaling pathway (19 genes), apoptosis signaling pathway (14 genes), inflammation mediated by chemokine and cytokine signaling pathway (23 genes), gonadotropin releasing hormone receptor pathway (21 genes), cell cycle (five genes), cytoskeletal regulation by Rho GTPase (eleven genes), pentose phosphate pathway (three genes), oxidative stress response (five genes), p38 MAPK pathway (six genes), angiotensin II-stimulated signaling through G proteins and beta-arrestin (six genes), fructose galactose metabolism (three genes), Ras pathways (nine genes), cadherin signaling pathway (two genes), cholesterol biosynthesis (three genes), axon guidance mediated by netrin (five genes), isoleucine biosynthesis (two genes), and B-cell activation (seven genes).

Table 1 Changes in gene expression in PBMCs of AMD patients before and after ranibizumab treatment

Fold change	Number of transcripts	P<0.05	P<0.02	P<0.01	P<0.005	P<0.001
FC all	22,283	4,506	2,086	817	25	4
FC >1.1	18,550	4,506	2,086	817	25	4
FC >1.5	9,518	4,474	2,086	817	25	4
FC >2.0	4,799	3,097	1,830	811	25	4
FC >.3.0	1,608	1,078	743	423	25	4

Notes: Volcano plot demonstrates P-value and fold change for transcripts which exhibit differential expression in PBMCs of AMD patients before and after ranibizumab treatment. Black indicates differentially expressed genes with P<0.05 and FC>2.0; gray indicates all genes with P>0.05.

Abbreviations: PBMCs, peripheral blood mononuclear cells; AMD, age-related macular degeneration; FC, fold change.

Table 2 PANTHER classification of biological processes, molecular functions, and cellular components significantly enriched in the set of differentially expressed genes

Biological process	Number of genes (observed/expected)	P-value	Biological process	Number of genes (observed/expected)	P-value
Metabolic process	1,172/925	<0.0001	Biological regulation	431/349	0.0005
Cellular process	865/639	<0.0001	Ion transport	115/74	0.0008
Primary metabolic process	986/771	<0.0001	Cellular component organization	164/114	0.0009
Developmental process	460/306	<0.0001	RNA splicing	56/29	0.0012
Cell communication	486/346	<0.0001	RNA splicing, via transesterification reactions	56/29	0.0012
System development	281/177	<0.0001	Vesicle-mediated transport	144/100	0.0024
Protein metabolic process	426/302	<0.0001	Synaptic transmission	75/45	0.0034
Multicellular organismal process	294/193	<0.0001	Endocytosis	72/43	0.0045
Single-multicellular organism process	294/193	<0.0001	Cellular protein modification process	177/129	0.0050
System process	251/159	<0.0001	mRNA splicing, via spliceosome	67/40	0.0076
Localization	397/283	<0.0001	Nucleobase-containing compound metabolic process	452/379	0.0080
Transport	387/275	<0.0001	Angiogenesis	49/26	0.0102
Neurological system process	203/130	<0.0001	Cellular defense response	69/42	0.0109
Nervous system development	169/108	<0.0001	Cell death	110/75	0.0135
Translation	85/44	<0.0001	Apoptotic process	110/75	0.0135
Mesoderm development	162/103	<0.0001	Death	110/75	0.0150
Intracellular protein transport	208/142	<0.0001	Reproduction	99/66	0.0162
Ectoderm development	153/98	<0.0001	Negative regulation of apoptotic process	39/20	0.0207
Cell–cell signaling	143/90	<0.0001	Heart development	47/26	0.0211
Protein transport	208/144	<0.0001	Visual perception	56/33	0.0218
Response to stimulus	248/179	<0.0001	Muscle organ development	68/42	0.0232
Cation transport	107/64	<0.0001	Cell cycle	196/150	0.0257
Cellular component morphogenesis	113/69	0.0001	Neuron-neuron synaptic transmission	23/10	0.0375
Anatomical structure morphogenesis	119/74	0.0001	Regulation of biological process	287/234	0.0415
Cellular component organization or biogenesis	177/122	0.0002	Gamete generation	86/57	0.0435
Immune system process	250/186	0.0004
Molecular function			Molecular function
Binding	810/637	<0.0001	Cation transmembrane transporter activity	71/40	0.0006
Catalytic activity	759/594	<0.0001	RNA binding	106/69	0.0021
Structural molecule activity	218/135	<0.0001	Nucleic acid binding	429/356	0.0039
Structural constituent of ribosome	60/22	<0.0001	Hydrogen ion transmembrane transporter activity	15/5	0.0255
Protein binding	413/307	<0.0001	Ion channel activity	62/38	0.0316
Transmembrane transporter activity	185/116	<0.0001	Oxidoreductase activity	99/68	0.0344
Transporter activity	192/123	<0.0001	mRNA binding	56/34	0.0378
Receptor binding	163/109	<0.0001	Structural constituent of Cytoskeleton	126/91	0.0436
Receptor activity	230/169	0.0004
Cellular component			Cellular component
Intracellular	213/154	<0.0001	Macromolecular complex	101/70	0.0085
Cell part	230/171	0.0002	Actin cytoskeleton	64/42	0.0311
Ribonucleoprotein complex	31/14	0.0040

Abbreviation: PANTHER, Protein Analysis Through Evolutionary Relationships.

Figure 3 PANTHER classification of differentially expressed genes.

Notes: Based on biological processes (A), molecular functions (B), and cellular components (C).
Abbreviations: PANTHER, Protein Analysis Through Evolutionary Relationships; GO, gene ontology.

In turn, molecular pathways that were significantly enriched in the list of down-regulated genes included cadherin signaling pathways (26 genes), TGFβ signaling pathway (17 genes), 5HT2 type receptor mediated signaling pathway (eleven genes), gonadotropin releasing hormone receptor pathway (29 genes), 5HT3 type receptor mediated signaling pathway (six genes), 5HT1 type receptor mediated signaling pathway (eight genes), heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (19 genes), CCKR signaling map (22 genes), endothelin signaling pathway (13 genes), 5HT4 type receptor mediated signaling pathway (five genes), 5-hydroxytryptamine degradation (three genes), integrin signaling pathway (21 genes), angiogenesis (18 genes), Wnt signaling pathway (31 genes), de novo purine biosynthesis (seven genes), heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway (14 genes), EGF receptor signaling pathway (15 genes), and oxidative stress response (five genes).

Discussion

The determination of systemic effects of intravitreal ranibizumab injections seems to be important.¹⁷ Therefore, this report focused on effects of intravitreal ranibizumab injections in patients with neovascular AMD on CRT both in treated and contralateral untreated eyes. Moreover, differences in the gene expression pattern in the PBMCs of patients with AMD after intravitreal injections of ranibizumab were revealed.

In our study, the mean CRT decreased in treated eye and untreated contralateral eye in patients with AMD 3 months after intravitreal injections of ranibizumab, with a sharper decrease in the treatment group. Many previous studies indicated that intravitreal injections of ranibizumab caused a significant reduction of CRT in treated eyes of patients with AMD.^18–23 However, the possibility of ranibizumab influence on the untreated eye still needs an explanation. Similar to our results, Wu and Sadda and Rouvas et al observed that intravitreal ranibizumab injections had therapeutic effects on the contralateral, un-injected eyes in patients with neovascular AMD.^8,24 Other authors also reported an effect of ranibizumab on the fellow eye of patients with various ocular diseases.^25–27 Acharya et al revealed a therapeutic effect on untreated contralateral eyes of patients after the third intravitreal dose of 0.5 mg ranibizumab but with bilateral uveitis-related cystoid macular edema.⁷ Similar to our results, these authors observed a reduction in CRT in treated and contralateral untreated eyes. However, the limitation of Acharya et al’s study is the small sample size. Likewise, Al-Dhibi and Khan revealed a bilateral reduction of uveitic cystoid macular edema following unilateral intravitreal bevacizumab injection in an 8-year-old child.²⁸ In turn, Sharma et al observed that an intravitreal dexamethasone implantation also seems to have a bilateral effect after unilateral injection in a 54-year-old patient with macular edema.²⁹ In another study, Hosseini et al observed that intravitreal injection of bevacizumab significantly changed ocular hemodynamic parameters of both the injected and the untreated fellow eyes of AMD patients.³⁰ It seems that this effect may be due to systemic spread of bevacizumab after intravitreal injections.

The decrease in CRT in the contralateral eyes may suggest that intravitreal injections of anti-VEGF agents can have systemic effects. It is known that after intravitreal injections bevacizumab can be detected in higher serum concentrations than ranibizumab and also has a systemically longer half-life.^31,32 Xu et al revealed that ranibizumab serum half-life is only approximately 2 hours. One reason for this may be that ranibizumab, an antibody fragment, lacks an Fc domain.³³ However, pharmacokinetics and bioavailability of ranibizumab are not yet fully known. Previous animal studies revealed small amounts of bevacizumab and ranibizumab in the serum and in the untreated contralateral eye after intravitreal administration.^34,35 Moreover, Christoforidis et al demonstrated in an animal model that anti-VEGF agent intravitreal injections can have an influence on the cutaneous wound healing.^36,37 However, only few published reports suggested that low serum levels of anti-VEGF agents may induce a therapeutic effect in the fellow eye of patients.^7,8,24,28 Additionally, the disruption of blood–retinal barrier in retinal diseases can also increase systemic absorption of anti-VEGF agents after intravitreal injections.^7,24

Another major issue related to anti-VEGF agents is understanding the molecular mechanism of action of these drugs. Golan et al, in their in vitro study, suggested that anti-VEGF agents may have an influence on gene expression involved in VEGF signaling pathways in different ways.³⁸ Therefore, the second part of this study focused on assessing the gene expression profile in PMBCs in AMD patients before and after intravitreal administration of ranibizumab. When we were launching our study there were only few published data regarding gene expression/protein level differences in blood samples of patients with AMD.^13–15 Mo et al determined serum cytokine levels in patients with AMD and suggested that IFN-γ-inducible protein-10 and eotaxin may be early biomarkers in this disease.³⁹ In turn, Falk et al did not observe significant differences in the blood expression levels of chemokine receptor CCR3 and chemokine CCL11 in patients with neovascular AMD.¹⁵ Moreover, these authors suggested that intravitreal injections of ranibizumab do not cause systemic alterations of expression of analyzed genes. In contrast, our results revealed changed expression of 3,097 transcripts after ranibizumab treatment. Among all these transcripts, 1,339 were up-regulated, whereas 1,758 were down-regulated. Similarly, Dabir et al, using microarray technique, analyzed systemic gene expression profile but in patients with diabetic macular edema.⁴⁰ These authors revealed that five genes were up-regulated and 105 genes were down-regulated among all studied groups, including diabetic, treatment responder, and treatment non-responder groups. Moreover, there was only one gene up-regulated between the diabetic and treatment responder groups. These authors also suggested that systemic levels of selected genes may be used to classify the treatment responders and non-responders. In addition, classification of differentially expressed genes based on functional category and pathways revealed that these genes play an important role in cancer, metabolism, ECM-receptor interaction, tricarboxylic acid cycle, retinol metabolism, TGF-β metabolism, VEGF pathway, cell adhesion molecules, p53 signaling, Jak-Stat signaling, and MAPKs pathways.⁴⁰ Similarly, our results revealed that differentially expressed genes before and after ranibizumab treatment in PBMCs of AMD patients play an important role in many of the aforementioned pathways and biological processes, including cellular, metabolic, cell communication, cell–cell signaling, cell adhesion, immune system, and angiogenesis.

In another study, Nassar et al determined levels of many serum cytokines in patients with AMD before and after ranibizumab treatment.¹³ These authors showed that IL-17 and TNF-α levels statistically significantly differ among patients with improvement, no change, and deterioration of CRT after anti-VEGF treatment, respectively. In turn, previous studies revealed that there were no statistically significant differences between serum/plasma VEGF concentrations before and after intravitreal ranibizumab injection measured by enzyme-linked immunosorbent assay.^41–43 However, the slightly increased serum VEGF concentration in 1 week after ranibizumab treatment may suggest systemic effects of intraocular anti-VEGF therapy.⁴¹ On the contrary, other authors observed a reduced VEGF level in serum of AMD patients after bevacizumab intravitreal injections.^31,44 Similarly, our results revealed inhibition of VEGF expression among differentially expressed genes in PBMCs of intravitreal ranibizumab treatment patients. In conclusion, our results suggest the potential systemic effects of anti-VEGF therapy for AMD. Our study revealed the reduction of CRT after intravitreal ranibizumab injections in patients with neovascular AMD both in treated and contralateral untreated eye.⁴⁵ Moreover, our study indicated a differential gene expression in PMBCs obtained from AMD patients before and after the intravitreal ranibizumab treatment. These results may contribute to a better understanding of the molecular mechanisms involved in the drug response of patients with AMD. Moreover, the differentiating genes determined by oligonucleotide microarray technique may also be the target of further research. Unfortunately, the major limitation of our study is a relatively small number of samples. Therefore, there is a need to study a larger population and carry out further analysis in order to better clarify the systemic effects of anti-VEGF-agents. Moreover, detailed examination of AMD therapy will also help to identify better treatment strategies for this disease.

Acknowledgments

This research was supported in part by PL-Grid Infrastructure (http://www.plgrid.pl/en).

Disclosure

The authors declare that there are no conflicts of interest.